ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

ClearPoint Neuro, Inc.NASDAQ: CLPT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $9.55M (cash outflow) rose 58.5% year over year, ahead of the +39.8% change in trailing-twelve-month net income. Sequentially, it rose 22.7% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.

Context

  • Net income amounted to 69.1% of revenue in FY2025, up 8.8 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$32.99M (+29.2%) for the fiscal year ending Dec 2026, a slowdown from the +35.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.55M+22.7% QoQ
Last fiscal yearDec 2025
-$25.54M+35.0% YoY
LTMMar 2026
-$29.07M+39.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.5%+52.2%-6.3 pp
1 year+35.0%+29.2%-5.9 pp
3-year CAGR+15.8%-1.6%-17.4 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(25.54M) USD
Year-over-year change
-35.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CLPT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.8% is the 4th highest of 10, against a peer median of +24.5%.
  • Net income amounts to 71.6% of revenue for CLPT, versus a peer median of 10.0%.
CLPT Competitors
Net Income for CLPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CMPSCOMPASS Pathways plcLTM Mar 2026$178.8M USD+29.8%+46.5%—
OFIXOrthofix Medical Inc.LTM Mar 2026$178.05M USD+24.5%+67.1%21.6%
VREXVarex Imaging CorporationLTM Apr 2026$82.7M USD+98.8%—9.6%
LABStandard BioTools Inc.LTM Mar 2026$78.21M USD+158.9%-26.7%90.7%
AVNSAvanos Medical, Inc.LTM Mar 2026$74.4M USD-80.7%—10.4%
CTKBCytek Biosciences, Inc.LTM Mar 2026$74M USD+557.6%—36.2%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$29.07M USD+39.8%+15.8%71.6%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$20.51M USD-54.7%-61.3%8.8%
SIBNSI-BONE, Inc.LTM Mar 2026$16.7M USD-37.1%-32.4%8.1%
SNDLSNDL Inc.LTM Mar 2026CA$10.98M CAD-89.7%-65.1%1.2%
Peer median (excluding CLPT) —+24.5%-29.6%10.0%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.41M)(16.43M)(22.09M)(18.91M)(25.54M)
Depreciation & Amortization692K777K1.51M1.9M982K
Deferred Income Tax202K0000
Stock-Based Compensation2.08M4.13M6.08M6.91M8.18M
Change in Working Capital(1.68M)(4.29M)(1.4M)1.4M(9.81M)
Accounts Receivables627K(211K)(1.8M)(1.21M)(268K)
Inventory(1.71M)(4.42M)1.25M743K(103K)
Accounts Payables(762K)1.59M03.11M(7.52M)
Other Working Capital165K(1.25M)(846K)(1.24M)(1.92M)
Other Non-Cash Items425K3.78M2.18M(245K)2.27M
Operating Cash Flow(12.7M)(16.17M)(13.72M)(8.95M)(23.93M)
Capital Expenditures(168K)(253K)(717K)(275K)(522K)
Acquisitions (Net)00001.14M
Purchases of Investments0(21.59M)000
Sales of Investments012M000
Other Investing Activities009.67M00
Investing Cash Flow(168K)(10.74M)8.95M(275K)615K
Debt Repayment000(10M)48.09M
Common Stock Issued46.79M745K016.15M3.95M
Common Stock Repurchased00(210K)00
Dividends Paid00000
Other Financing Activities90K(336K)506K40K(1.86M)
Financing Cash Flow46.88M409K296K6.19M50.18M
Effect of Forex Changes00000
Net Change in Cash34.01M(26.49M)(4.48M)(3.04M)26.87M
Free Cash Flow(12.87M)(16.42M)(14.44M)(9.23M)(24.45M)

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.